Manufacturer
GLAXOSMITHKLINE BIOLOGICALS S.A
Contents
Per 0.5 mL Diphtheria toxoid not <30 IU, tetanus toxoid not <40 IU, pertussis toxoid 25 mcg, filamentous haemagglutinin 25 mcg, pertactin 8 mcg, HBsAg 10 mcg, inactivated poliovirus [type 1 (Mahoney strain) 40 D-antigen unit, type 2 (MEF-1 strain) 8 D-antigen unit & type 3 (Saukett strain) 32 D-antigen unit], HIB polysaccharide (PRP) 10 mcg (conjugated to tetanus toxoid as carrier protein approx 25 mcg)
Indication
Primary immunisation against DPT, hepatitis B, poliomyelitis & HIB in infants from 6 wk & in infants who received 1st dose of hepatitis vaccine at birth.
Instruction
Deep IM inj Primary immunisation Full-term infant 3 doses of 0.5 mL w/ at least 1 mth interval between primary doses. Booster dose to be given at least 6 mth after last priming dose & before 18 mth; 2 doses of 0.5 mL w/ at least 1 mth interval between primary doses. Booster dose to be given at least 6 mth after last priming dose & between 11 & 13 mth. Preterm infant born after at least 24 wk of gestation 3 doses of 0.5 mL w/ at least 1 mth of interval between primary doses. Booster dose to be given at least 6 mth after last priming dose & before 18 mth.
Drug interaction
Higher febrile reaction rate w/ pneumococcal conjugate vaccine. Adequate immunologic response may not be achieved w/ immunosuppressants.
Malaysia
